Thrombogenesis and thrombotic disorders based on 'two-path unifying theory of hemostasis': Philosophical, physiological, and phenotypical interpretation

Blood Coagulation and Fibrinolysis

Volumn 29, Issue 7, 2018, Pages 585-595

  Chang, Jae C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

disseminated intravascular coagulation; disseminated intravascular microthrombosis; fibrin clot; fibrinogenesis; hemostasis; macrothrombogenesis; macrothrombosis; microthrombogenesis; microthrombosis; vascular microthrombotic disease

Indexed keywords

ARTICLE; BLOOD CLOTTING; CHRONIC DISEASE; DISEASE CLASSIFICATION; HEMOSTASIS; HUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; THROMBOSIS; WOUND HEALING; METABOLISM; PHYSIOLOGY; THEORETICAL MODEL;

THROMBOPLASTIN; VON WILLEBRAND FACTOR;

HEMOSTASIS; HUMANS; MODELS, THEORETICAL; THROMBOPLASTIN; THROMBOSIS; VON WILLEBRAND FACTOR; WOUND HEALING;

EID: 85055079269     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000769     Document Type: Article

References (63)

1. Chang JC. Hemostasis based on a novel 'two-path unifying theory' and classification of hemostatic disorders. Blood Coagul Fibrinolysis 2018; [Epub ahead of print].
2. Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J 2018; 16:20.
3. Chang JC. Disseminated intravascular coagulation (DIC): Is it fact or fancy?. Blood Coagul Fibrinolysis 2018; 29:330-337.
4. Chang JC. Molecular pathogenesis of STEC-HUS caused by endothelial heterogeneity and unprotected complement activation, leading to endotheliopathy and impaired ADAMTS13 activity: Based on twoactivation theory of the endothelium and vascular microthrombotic disease. Nephrol Renal Dis 2017; 2:1-8.
5. Ribeiro DR, Cambruzzi E, Schmidt MM, Quadros AS. Thrombosis in STelevationmyocardial infarction: Insights from thrombi retrieved by aspiration thrombectomy. World J Cardiol 2016; 8:362-367.
6. Habito CR, Kalva SP. Inferior vena cava filter thrombosis: A review of current concepts, evidence, and approach to management. Hosp Pract 2011; 39:79-86.
7. Muzaffar M, Fatimi SH, Tariq M, Hanif HM. Subclavian steal syndrome secondary to subclavian artery thrombosis in a patient with homocysteinemia and its successful treatment. J Pak Med Assoc 2012; 62:1118-1120.
8. Kimball AS, Obi AT, Diaz JA, Henke PK. The emerging role of NETs in venous thrombosis and immunothrombosis. Front Immunol 2016; 7:236.
9. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13:34-45.
10. Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care 2015; 19:72.
11. Chang JC. Thrombocytopenia in critically ill patients due to vascular microthrombotic disease: Pathogenesis based on 'two activation theory of the endothelium'. Vascul Dis Ther 2017; 2:1-7.
12. Chang JC. Viral hemorrhagic fevers due to endotheliopathy-associated disseminated intravascular microthrombosis and hepatic coagulopathy: Pathogenesis based on 'two activation theory of the endothelium'. Clin Microbiol Infect Dis 2017; 2:1-6.
13. Mann KG, Krudysz-Amblo J, Butenas S. Tissue factor controversies. Thromb Res 2012; 129 (Suppl 2):S5-S7.
14. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24:1015-1022.
15. Wolberg AS, Mast AE. Tissue factor and factor VIIa - hemostasis and beyond. Thromb Res 2012; 129 (Suppl 2):S1-S4.
16. Rao LV, Kothari H, Pendurthi UR. Tissue factor encryption and decryption: Facts and controversies. Thromb Res 2012; 129 (Suppl 2): S13-S17.
17. Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed) 2012; 4:289-299.
18. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96:170-5.
19. van der Poll T, Levi M. Crosstalk between inflammation and coagulation: The lessons of sepsis. Curr Vasc Pharmacol 2012; 10:632-638.
20. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417-430.
21. Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014; 111:570-574.
22. Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A 2016; 89:111-122.
23. Bogdanov VY, Versteeg HH. Soluble tissue factor' in the 21st century: Definitions, biochemistry, and pathophysiological role in thrombus formation. Semin Thromb Hemost 2015; 41:700-707.
24. Sieve I, Münster-Kühnel AK, Hilfiker-Kleiner D. Regulation and function of endothelial glycocalyx layer in vascular diseases. Vascul Pharmacol 2018; 100:26-33.
25. Mackman N, Gruber A. Platelet polyphosphate: An endogenous activator of coagulation factor XII. J Thromb Haemost 2010; 8:865-867.
26. Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13:34-39.
27. Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. Clin Med Res 2010; 8:168-172.
28. Bagot CN, Arya R. Virchow and his triad: A question of attribution. Br J Haematol 2008; 143:180-190.
29. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care 2014; 2:67.
30. O'Brien M. The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med 2012; 27:46-52.
31. Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013; 109:416-420.
32. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2:16037.
33. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001; 16:167-177.
34. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: Dead end or one way?. Crit Care Med 2012; 40:2704-2708.
35. Dellinger RP. Inflammation and coagulation: Implications for the septic patient. Clin Infect Dis 2003; 36:1259-1265.
36. Chang JC. A thought on possible pathogenesis of ebola viral hemorrhagic disease and potential treatments: Could it be thrombotic thrombocytopenic purpura-like syndrome?. Ther Apher Dial 2015; 20:93-98.
37. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, et al. Ultralarge multimers of von Willebrand factor form spontaneous highstrength bonds with the platelet glycoprotein Ib-IX complex: Studies using optical tweezers. Blood 2002; 99:3971-3977.
38. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108:1447-1452.
39. Hoffman M. Some things I thought I knew about tissue factor that turn out to be wrong. Thromb Res 2008; 122 (Suppl 1):S73-S77.
40. Gale AJ. Continuing education course #2: Current understanding of hemostasis. Toxicol Pathol 2011; 39:273-280.
41. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2007; 120 (Suppl 1):S5-S9.
42. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16:17-20.
43. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120(Suppl 1):S5-S9.
44. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: Focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25:206-216.
45. Mourik MJ, Valentijn JA, Voorberg J, Koster AJ, Valentijn KM, Eikenboom J. von Willebrand factor remodeling during exocytosis from vascular endothelial cells. J Thromb Haemost 2013; 11:2009-2019.
46. Towne JB, Bernhard VM, Hussey C, Garancis JC. White clot syndrome. Peripheral vascular complications of heparin therapy. Arch Surg 1979; 114:372-377.
47. Chang JC. White clot syndrome associated with heparin-induced thrombocytopenia: A review of 23 cases. Heart Lung 1987; 16:403-407.
48. Huang J, Roth R, Heuser JE, Sadler E. Integrin avb3 on human endothelial cells binds von Willebrand factor strings under fluidshear stress. Blood 2009; 113:1589-1597.
49. Chauhan AK, Goerge T, Schneider SW, Wagner DD. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 2007; 5:583-589.
50. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood 2013; 121:270-277.
51. Smith SA. State -of-the-art review. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio) 2009; 19:3-10.
52. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord 2015; 15:130.
53. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114:4886-4896.
54. Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 1995; 17:140-147.
55. Allen S, Moran N. Cell adhesion molecules: Therapeutic targets for inhibition of inflammatory states. Semin Thromb Hemost 2015; 41:563-571.
56. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011; 25:155-167.
57. Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes. Hematol Oncol Clin North Am 2015; 29:509-524.
58. Bakker CM, Knot EA, Stibbe J, Wilson JH. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992; 15:330-335.
59. Joist JH. AICF and DIC in liver cirrhosis: Expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94:2801-2803.
60. Bertaglia E, Belmonte P, Vertolli U, Azzurro M, Martines D. Bleeding in cirrhotic patients: A precipitating factor due to intravascular coagulation or to hepatic failure?. Haemostasis 1983; 13:328-334.
61. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12:7725-7736.
62. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6:1247-1257.
63. Amarapurkar PD, Amarapurkar DN. Management of coagulopathy in patients with decompensated liver cirrhosis. Int J Hepatol 2011; 2011:695470.